All 21 committee members voted to approve the biologic as a treatment for ulcerative colitis and 20 of 21 committee members voted for approval as a Crohn’s disease treatment.
The advisory committees’ decision is non-binding, but will be taken into consideration when the FDA makes its decision on Takeda Pharmaceutical’s Biologics License Application for vedolizumab.
More Articles on Gastroenterology:
Norwalk Hospital Adds Dr. Summa S. Magge
FDA Advisory Committee Reviews Vedolizumab Safety Concerns
Joint Research Team Discovers New Method for Developing Anti-Diarrheal Drugs
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
